TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.

Blood Adv · 2023 · PMC10480533 · PMID 37078708

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, TP53 -mutated PTCL showed a trend toward a lower frequency of CRs compared with TP53 -unmutated PTCL, suggesting inherent chemoresistance in these cases.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.